4 Stocks with Yields Above 5% to Help Your Retirement Portfolio Grow

NYSE: GSK | GlaxoSmithKline PLC  News, Ratings, and Charts

GSK – Because the inflationary environment and supply chain constraints could keep the overall stock market under pressure in the near term, we think it could be wise to bet on quality dividend stocks to benefit from a steady stream of income. GlaxoSmithKline (GSK), Fortescue (FSUGY), Kronos (KRO), and USD Partners (USDP) are established companies that offer 5%-plus dividend yields. So, it could be wise to add them to one’s retirement portfolio. Read on.

According to data from FactSet, 41 S&P 500 companies have reported third-quarter results so far, with 80% of them topping EPS expectations. However, U.S. oil prices jumped another 1%, surpassing $83 per barrel, their highest level since October 2014. In addition, the 10-year Treasury yield this week started  edging  back up toward 1.62%. So, market volatility will likely continue amid increasing inflation.

Against this backdrop, investors are turning to dividend-yielding stocks to ensure a steady income stream. Investors’ interest in dividend stocks is evidenced by the SPDR S&P Dividend ETF’s (SDY) 3.2% returns over the past month versus the SPDR S&P 500 Trust ETF’s (SPY) 2.2% returns.

So, it could be wise to scoop up the shares of GlaxoSmithKline plc (GSK), Fortescue Metals Group Limited (FSUGY), Kronos Worldwide, Inc. (KRO), and USD Partners LP (USDP) on  their fundamental strength and attractive dividends. Their current dividend yields exceed 5%.

GlaxoSmithKline plc (GSK)

Based in Brentford, in the United Kingdom, healthcare company GSK operates through two segments: Pharmaceuticals and Vaccines. The company’s main research area includes respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, vaccines, immuno-inflammation, oncology, and rare diseases.

On August 17, GSK announced that the FDA had approved a new indication for JEMPERLI, a programmed cell death receptor-1 blocking antibody, to treat adult patients with mismatch repair-deficient recurrent or advanced solid tumors. This therapy is expected to boost the company’s revenue in the near to midterm.

GSK’s dividend pay-outs have grown at a 0.23% CAGR over the past five years and 9.59% over the past three years. While its four-year average dividend yield is 5.30%, its current dividend translates to a 5.63% yield. It paid a $0.52 per share quarterly dividend on October 7, 2021, yielding an annual dividend of $2.20.

GSK’s turnover increased 6% year-over-year to £8.09 billion ($11.06 billion) for the second quarter, ended June 30, 2021. Its adjusted operating profit grew 23% year-over-year to £2.16 billion ($2.95 billion), while its adjusted earnings per share increased 46% year-over-year to 28.10p.

Analysts expect GSK’s EPS and revenue to increase 8.4% and 5.2%, respectively, year-over-year to $3.11 and $47.68 billion in its fiscal year 2022. In addition, it surpassed the consensus EPS estimates in three of the trailing four quarters. Over the past year, the stock has gained 8.4% in price to close Friday’s trading session at $39.01.

It’s no surprise that GSK has an overall A rating, which equates to a Strong Buy in our POWR Ratings system. The POWR Ratings assess stocks by 118 distinct factors, each with its own weighting.

The stock has an A grade for Growth and Value and a B grade for Stability and Sentiment. Click here to see GSK’s ratings for Quality and Momentum as well. GSK is ranked #3 of 211 stocks in the Medical – Pharmaceuticals industry.

Click here to checkout our Healthcare Sector Report for 2021

Fortescue Metals Group Limited (FSUGY)

FSUGY explores for, develops, produces, processes, and sells iron ore, copper, and gold deposits. It owns and operates the Chichester Hub in the Chichester ranges and Solomon Hub in Hamersley ranges of Pilbara, Western Australia. In addition, the East Perth, Australia, company holds a portfolio of properties situated in Ecuador and Argentina, and it also provides port towage services.

FSUGY’s dividend pay-outs have grown at an 87.31% CAGR over the past five years and 148.12% over the past three years. While its four-year average dividend yield is 9.64%, its current dividend translates to a 27.76% yield. Its annual dividend is $6.05. Also, FSUGY paid a $3.03 per share semi-annual dividend on October 7.

For its fiscal year ended June 30, 2021, FSUGY’s revenue increased 74% year-over-year to $22.28 billion. Its underlying EBITDA rose 96% year-over-year to $16.37 billion. The company’s underlying net profit after tax increased 118% year-over-year to $10.35 billion, while its EPS grew 117% year-over-year to 335 cents.

FSUGY’s strong fundamentals are reflected in its POWR Ratings. The stock has an overall A rating, which equates to a Strong Buy in our proprietary rating system. It has an A grade for Quality and Value as well.

We have also graded FSUGY for Growth, Sentiment, Momentum, and Stability. Click here to access all FSUGY’s ratings. FSUGY is ranked #2 of 41 stocks in the Miners – Diversified industry.

Kronos Worldwide, Inc. (KRO)

KRO produces and markets titanium dioxide pigments internationally. The Dallas, Tex., company also produces ilmenite, iron-based chemicals, titanium oxychloride, and titanyl sulfate. In addition, the company provides technical services for its products. It sells its products under the KRONOS brand through agents and distributors.

KRO’s dividend pay-outs have grown at a 3.71% CAGR over the past five years and 2.94% over the past three years. While its four-year average dividend yield is 4.91%, its current dividend translates to a 5.45% yield. It paid a $0.18 per share quarterly dividend on September 16, 2021, yielding a $0.72 annual dividend.

KRO’s net sales increased 24% year-over-year to $478.60 million for the second quarter, ended June 30, 2021. Its EBITDA grew 23.3% year-over-year to $52.90 million, while its net income increased 38.2% year-over-year to $25.70 million. Also, its EPS increased 37.5% year-over-year to $0.22.

KRO’s EPS is expected to come in at $0.20 for the quarter ending December 30, 2021, representing a 122.2% year-over-year increase. In addition, the company’s revenue is expected to increase 15.2% year-over-year to $1.89 billion in its fiscal year 2021.

KRO’s POWR Ratings reflect this promising outlook. The company has an overall A rating, which translates to a Strong Buy in our proprietary rating system. The stock has an A grade for Value, and a B grade for Stability and Sentiment.

Within the A-rated Chemicals industry, KRO is ranked #7 of 93 stocks. To see KRO’s ratings for Growth, Momentum, and Quality as well, click here.

USD Partners LP (USDP)

USDP in Houston, Tex., acquires, develops, and operates midstream infrastructure assets and logistics solutions for crude oil, biofuels, and other energy-related products in the United States and Canada. The company operates through two segments: Terminalling Services and Fleet Services.

On August 16, 2021, USDP announced an expansion of the downstream connectivity at its Stroud terminal. Jim Albertson, Senior Vice President, Commercial Development, said, “This expansion facilitates greater market access and enhances the Stroud terminal’s ability to increase its customer base and fee-generating commitments.”

USDP’s four-year average dividend yield is 16.62%, its current dividend translates to a 6.93% yield. Its annual dividend is $0.46. Also, it paid a $0.12 per share quarterly dividend on August 13.

USDP’s total revenues increased 22.2% year-over-year to $33.52 million for the second quarter, ended June 30, 2021. The company’s operating income grew 83% year-over-year to $9.15 million, while its net income increased 466.3% year-over-year to $6.72 million. Also, its adjusted EBITDA increased 27.7% year-over-year to $16.32 million.

For its fiscal year 2022, analysts expect USDP’s EPS and revenue to increase 5.2% and 4.7% year-over-year to $1.01 and $134.53 million, respectively. The stock has gained 112% in price over the past year to close Friday’s trading session at $6.70.

USDP’s POWR Ratings reflect solid prospects. The company has an overall rating of A, which translates to a Strong Buy in our proprietary rating system. In addition, it has an A grade for Quality, and a B grade for Momentum, Value, Stability, and Sentiment.

Click here to see the additional POWR Rating for USDP (Growth). USDP is ranked #3 of 11 stocks in the A-rated MLPs – Other industry.


GSK shares fell $0.01 (-0.03%) in after-hours trading Monday. Year-to-date, GSK has gained 9.66%, versus a 20.78% rise in the benchmark S&P 500 index during the same period.


About the Author: Nimesh Jaiswal


Nimesh Jaiswal's fervent interest in analyzing and interpreting financial data led him to a career as a financial analyst and journalist. The importance of financial statements in driving a stock’s price is the key approach that he follows while advising investors in his articles. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
GSKGet RatingGet RatingGet Rating
FSUGYGet RatingGet RatingGet Rating
KROGet RatingGet RatingGet Rating
USDPGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

Stock Market “Nausea Index” Going Off

The stock market (SPY) has seen fresh lows this week scaring many investors into selling their positions. On the other hand, 40 year investment veteran shares a proprietary market indicator that points to a significant bounce coming soon. Is he right? You be the judge by reading below.

:  |  News, Ratings, and Charts

3 Stocks that Are Thriving in an Inflationary Environment

Inflation is one of the biggest threats facing the economy. One profitable strategy during this period of high inflation is to focus on stocks that have pricing power, as these companies’ margins will continue to expand. In contrast, stocks without pricing power are likely to underperform as margin compression erodes EPS. Therefore, investors should consider buying these 3 stocks that are thriving in this inflationary environment: Olin (OLN), Nucor (NUE), and Chemours (CC).

:  |  News, Ratings, and Charts

Is the Bear Market Here?

We are witnessing the nastiest stock market (SPY) correction since Covid first came on the scene. That has some pondering if the next bear market is upon us. 40 year veteran investor Steve Reitmeister gives his clear eyed view on the market outlook and trading plan in this timely commentary. Get the full story below...

:  |  News, Ratings, and Charts

4 Best Value Stocks to Buy in January

In times of high inflation, value stocks tend to outperform growth stocks and have done so over the past year. Amid the rising inflationary pressure and looming interest rate hikes, fundamentally sound value stocks ArcelorMittal (MT), Covestro (COVTY), KT Corporation (KT), and Nature’s Sunshine (NATR) could be solid bets.

:  |  News, Ratings, and Charts

Is the Bear Market Here?

We are witnessing the nastiest stock market (SPY) correction since Covid first came on the scene. That has some pondering if the next bear market is upon us. 40 year veteran investor Steve Reitmeister gives his clear eyed view on the market outlook and trading plan in this timely commentary. Get the full story below...

Read More Stories

More GlaxoSmithKline PLC (GSK) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All GSK News